ARCT Arcturus Therapeutics Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1768224 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.7%
TTM net income YoY-30.8%
TTM EPS YoY-26.0%
Revenue 3-yr CAGR-53.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-311.2%
Net margin-285.9%
FCF margin-204.7%
EBITDA margin-302.9%
Returns
ROE-44.4%
ROA-35.1%
ROIC (approx.)-533.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets21.6%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue-0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $82.03M | $152.31M |
| R&D expense | $112.21M | $195.16M |
| SG&A expense | $46.08M | $52.82M |
| Operating income | -$76.26M | -$95.67M |
| Pretax income | -$65.78M | -$80.94M |
| Income tax | — | -$4,000 |
| Net income | -$65.78M | -$80.94M |
| EBITDA | -$73.23M | -$92.12M |
| EPS (basic) | -2.40 | -3.00 |
| EPS (diluted) | -2.40 | -3.00 |
| Weighted avg. shares (diluted) | 27.39M | 27.00M |
| Balance sheet | ||
| Cash & equivalents | $230.91M | $293.91M |
| Receivables | $5.56M | $3.97M |
| Current assets | $241.45M | $305.98M |
| PP&E, net | $6.74M | $9.53M |
| Total assets | $271.15M | $344.07M |
| Current liabilities | $36.38M | $65.49M |
| Total liabilities | $57.16M | $103.09M |
| Shareholders' equity | $213.99M | $240.98M |
| Shares outstanding | 28.41M | 27.00M |
| Cash flow statement | ||
| Operating cash flow | -$74.27M | -$59.75M |
| Capital expenditure | $230,000 | $648,000 |
| Free cash flow | -$74.50M | -$60.40M |
| Investing cash flow | -$230,000 | -$648,000 |
| Financing cash flow | $13.38M | $5.42M |
| Depreciation & amortization | $3.02M | $3.54M |
| Stock-based compensation | $25.41M | $37.99M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.